Welcome to our dedicated page for Sandoz Group news (Ticker: SDZNY), a resource for investors and traders seeking the latest updates and insights on Sandoz Group stock.
Sandoz Group AG (SDZNY) generates frequent news flow as a global player in generic and biosimilar medicines. Company announcements cover product launches, clinical and pipeline updates, manufacturing investments, sustainability initiatives and corporate developments. Investors and healthcare observers following Sandoz news can see how the company’s generics and biosimilars strategy evolves across key therapeutic areas and geographies.
Recent news has highlighted US launches of denosumab biosimilars WYOST and Jubbonti, described as the first and only FDA‑approved interchangeable denosumab biosimilars available in the US, and the introduction of a generic iron sucrose injection for iron deficiency anemia in patients with chronic kidney disease. In Europe, Sandoz has reported the launch of the Pyzchiva (ustekinumab) autoinjector, the first ustekinumab biosimilar in Europe commercially available in a pre‑filled pen, aimed at improving self‑administration for patients with chronic inflammatory diseases.
News items also cover strategic manufacturing and sustainability moves, such as breaking ground on a new biosimilars production center in Brnik, Slovenia, and a 10‑year virtual power purchase agreement with Elawan Energy for solar projects in Spain, expected to meet nearly 90% of Sandoz electricity demand for European operations. Financial updates, including quarterly and half‑year net‑sales reports and guidance confirmations, provide insight into performance trends across generics and biosimilars and by region.
Visitors to the Sandoz news page on Stock Titan can review these developments over time, track new collaborations and potential acquisitions, and monitor how regulatory and legal milestones—such as biosimilar development decisions or competition‑related litigation—may influence the company’s trajectory.
Sandoz (SIX:SDZ/OTCQX:SDZNY) has filed an antitrust lawsuit against Amgen in the US District Court for the Eastern District of Virginia regarding access to its etanercept biosimilar. The litigation alleges that Amgen has unlawfully blocked competition by purchasing and using certain patent rights to maintain market dominance for Enbrel®, which generated USD 3.3 billion in US revenue in 2024.
Despite receiving FDA approval in 2016 for Erelzi® (etanercept-szzs), Sandoz has been unable to launch this biosimilar treatment. The medication could potentially benefit approximately 7.5 million Americans living with chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and other conditions.
Sandoz is seeking both an injunction to prevent Amgen from using patent rights to block biosimilar competition and damages, which could be tripled under applicable laws.
Sandoz (SIX:SDZ/OTCQX:SDZNY) has filed an antitrust lawsuit against Amgen in the US District Court for the Eastern District of Virginia regarding access to its etanercept biosimilar. The litigation challenges Amgen's market dominance with Enbrel®, which generated USD 3.3 billion in US revenue in 2024.
The lawsuit alleges that Amgen unlawfully purchased and used patent rights to block competition from Sandoz's biosimilar Erelzi®, which received FDA approval in 2016. Despite approval nearly a decade ago, the biosimilar remains blocked from the US market, affecting approximately 7.5 million Americans living with chronic inflammatory diseases who could benefit from more affordable treatment options.
Sandoz is seeking both an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and damages, which could be tripled under applicable laws.
Sandoz (SIX:SDZ/OTCQX:SDZNY) has announced significant financial restructuring moves to strengthen its balance sheet. The company has fully repaid USD 750 million equivalent in USD and EUR term loans from September 2023 through three successful bond issuances:
- A dual-tranche CHF bond: CHF 165M (3-year, 1.25% coupon) and CHF 235M (8-year, 1.75% coupon)
- A EUR 500M single-tranche bond (10-year, 4.0% coupon)
The EUR tranche achieved a six-times oversubscription rate. Additionally, Sandoz has secured a new USD 2.0 billion multi-currency revolving credit facility, replacing the previous USD 1.25 billion facility. These transactions are expected to reduce the annual interest rate on gross debt to below 4%, while extending the debt-maturity profile to 2035 with an average maturity of 5.5 years.
Sandoz (SIX:SDZ/OTCQX:SDZNY) announces the US launch of Pyzchiva® (ustekinumab-ttwe), a biosimilar medicine for treating chronic inflammatory diseases. The product, developed by Samsung Bioepis and commercialized by Sandoz, is now available across the US with the same indications as reference medicine Stelara®.
This launch represents a key value driver for Sandoz's growth strategy, advancing its goal to become the leading biosimilar provider in the US. The product offers a complete suite of dosing options and enhanced stability features, including re-refrigeration capability. Sandoz expects to obtain interchangeability status in the first half of 2025.
The company is providing comprehensive patient support resources, including insurance coverage information, self-injection training, and a co-pay program for commercially insured patients. This launch follows a settlement agreement with Johnson & Johnson and a commercialization agreement with Samsung Bioepis, giving Sandoz rights to commercialize Pyzchiva® in multiple territories.
Sandoz, the global leader in generic and biosimilar medicines, has announced key leadership changes. Francisco Ballester, President Region International and Executive Committee member, will retire on March 1, 2025, after 34 years of service. Peter Stenico, currently Global Platform Head Biosimilars and Country President Sandoz Austria, will succeed Ballester as President Region International and join the Sandoz Executive Committee.
Ballester has been responsible since 2019 for driving business growth and access in markets outside North America and Europe. Stenico, who joined Sandoz in 2002, brings extensive experience in biosimilars and generics through various strategic, M&A, and commercial roles. He previously served as Country Head for Sandoz Germany and President of the German Generics Association.
Sandoz, the global leader in generic and biosimilar medicines, presented its strategic roadmap at the 43rd Annual J.P. Morgan Healthcare Conference. The company operates in a USD 200 billion market for generics and biosimilars, expected to grow at 7% annually for the next decade.
Key highlights include:
- An expanded biosimilar pipeline now comprising 28 molecules
- Three planned US biosimilar launches in 2025
- Strong market position with Europe representing half of total sales
- Significant market opportunity with reference medicines worth over USD 400 billion losing exclusivity from 2029-2034
The company reported over 30% sales growth in the first nine months of 2024, with biosimilars as the primary growth driver. Sandoz plans five biosimilar launches in the mid-term, including Pyzchiva®, Tyruko®, Wyost®/Jubbonti®, and Afqlir®. The company also has an ambitious GLP-1 strategy in place, addressing opportunities through internal capabilities and external partnerships.
Sandoz has announced significant steps to resolve the US Generic Drug Antitrust Class Action Litigation. The company has reached a $275 million settlement with end payer plaintiffs' class, to be paid by December 31, 2024. Additionally, Sandoz has established a $265 million provision for outstanding claims from opt-out plaintiffs and State Attorneys' General.
The settlement with end payer plaintiffs includes no admission of wrongdoing and covers alleged conduct between 2009 and 2019. Class members can opt out, potentially reducing the settlement by up to $45 million. The agreement follows previous settlements with the US Department of Justice (2020-2021) and direct purchaser plaintiffs (February 2024).
These financial commitments will be reflected in Sandoz's 2024 financial results but will not affect the company's full-year 2024 and mid-term guidance.
Sandoz has received European Commission approval for Afqlir® (aflibercept), a biosimilar to Eylea®, for treating various retinal diseases including neovascular age-related macular degeneration (nAMD). The treatment will be available as 2 mg vial kit and pre-filled syringe for intravitreal injection, with launch expected in Q4 2025.
nAMD, affecting the central vision zone, is responsible for 90% of severe vision loss in AMD cases. Out of 3.6 million patients with nAMD across major markets, 2.5 million are diagnosed but only 1.7 million receive treatment.
Sandoz reported strong Q3 2024 performance with net sales of USD 2.6 billion, up 12% in constant currencies. Nine-month net sales reached USD 7.6 billion, up 9%. The growth was driven by exceptional biosimilars performance, up 37% in Q3, and accelerating generics growth in Europe. Biosimilar success was attributed to Hyrimoz uptake in the US, Cimerli acquisition, and strong Omnitrope demand. The company received US FDA approvals for Pyzchiva and Enzeevu, while launching Pyzchiva in Europe. Based on strong momentum, Sandoz increased its full-year 2024 net sales guidance to high-single digit growth and confirmed core EBITDA margin guidance of around 20%.
Sandoz, a global leader in generic and biosimilar medicines, has launched a generic paclitaxel formulation in the US. This is the first FDA-approved abbreviated new drug application (ANDA) to reference the original medicine. The product is a single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer treatment.
The launch follows FDA approval on October 8, 2024, and is expected to be a near-term growth driver in the US market. Developed in partnership with Jiangsu Hengrui Pharmaceuticals Co., , this generic version references Abraxane® for Injectable Suspension. Keren Haruvi, President of Sandoz North America, emphasized the company's commitment to providing access to life-changing medicines, noting that an estimated 168,000 women in the US are living with metastatic breast cancer.